

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	2066263
<b>Application Number:</b>	10527866
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	2052
<b>Title of Invention:</b>	Pyrrazolo[3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors
<b>First Named Inventor/Applicant Name:</b>	David George Allen
<b>Customer Number:</b>	20462
<b>Filer:</b>	James Marlin Kanagy/Ellen Kelleher
<b>Filer Authorized By:</b>	James Marlin Kanagy
<b>Attorney Docket Number:</b>	P33108
<b>Receipt Date:</b>	09-AUG-2007
<b>Filing Date:</b>	27-SEP-2005
<b>Time Stamp:</b>	14:57:06
<b>Application Type:</b>	U.S. National Stage under 35 USC 371

### Payment information:

Submitted with Payment	no
------------------------	----

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes) /Message Digest	Multi Part /.zip	Pages (if appl.)
1	Information Disclosure Statement (IDS) Filed	IDS_1449_JMK.pdf	175504	no	4
			77d968dca98991195e65d747481364e9d5b31		

**Warnings:**

<b>Information:</b>					
This is not an USPTO supplied IDS fillable form					
2	NPL Documents	Bare_1989JMC_pyrazolopyridine_ester_amide_anxiolytic_agents_1.pdf	1405767 e338b141197a0f58a33a5d138593d47676323599	no	13
<b>Warnings:</b>					
<b>Information:</b>					
3	NPL Documents	Beer_1978_Pharmacol_Biochem_Behavior_SQ65_396_anxiety_agent.pdf	641939 d1d700c66507c1656ab3099d439a9ea5179558a	no	3
<b>Warnings:</b>					
<b>Information:</b>					
4	NPL Documents	Bondavalli_2002_JMC_pyrazolopyridine_5_ester_A1_Antagonists1.pdf	18648856 19051f515c7a979b0c4450af1b1d1d45542711c267	no	13
<b>Warnings:</b>					
<b>Information:</b>					
5	Foreign Reference	CA1003419_Squibb_pyrazolo_3_4_b_pyridines.pdf	5455104 53cd34cb6775c17ab781786ce62ab8a75c6d	no	25
<b>Warnings:</b>					
<b>Information:</b>					
6	Foreign Reference	CH553799_A5_Squibb_1_H_1_furanylmethyl_pyrazolopyridines.pdf	589454 43lea2670ba2dc79d4d5f1a2cd7f599e28ab9ef	no	8
<b>Warnings:</b>					
<b>Information:</b>					
7	Foreign Reference	CH553799_Squibb_pyrazolopyridines_structures_EN_translation.pdf	2836095 ef921ca5b0b8e2af9c3b2ad43d1e516d0ae8513d9	no	17
<b>Warnings:</b>					
<b>Information:</b>					
8	NPL Documents	Chakravorti_1978_Indian_J_Chem_isoquinolylpyrazolo_3_4_b_pyridines.pdf	657208 a3d096ad3c43eca851c7f1b1d1c4c23b64d5938c	no	3
<b>Warnings:</b>					
<b>Information:</b>					
9	NPL Documents	Chasin_1972_Biochem_Pharmacol_SQ20009_as_PDE_inhibitor.pdf	1148135 d7a5154b561de3d4a33bee41eac0207c1a59a2b	no	8
<b>Warnings:</b>					
<b>Information:</b>					

10	Information Disclosure Statement Letter	Chem_Abs_Reg_no_502143_17_1_NSC235755_8_April_2003.pdf	83141 02f01140d64d29824a3a458814c4d5150c19f74	no	1
<b>Warnings:</b>					
<b>Information:</b>					
11	NPL Documents	Daly_MedChemRes_1994_1_Me_4_substd_pyrazolo_3_4_b_pyridines_0A1_A2_activity.pdf	2883111 1531e7625cd52b31934c28930cd0f93d5e2d6e1f99	no	14
<b>Warnings:</b>					
<b>Information:</b>					
12	NPL Documents	Davis_1987_J_Comp_Aided_Mol_Design_modelling_PDE_substrates_inhibitors.pdf	2204363 d643eb24cc3a3f920922a4d5af1987cc5665c7	no	23
<b>Warnings:</b>					
<b>Information:</b>					
13	NPL Documents	de_Mello_2004_JMedChem_47_5427_32_Antileishmanial_Pyrazolopyridines1.pdf	7322138 004e1d421624fba07b22a646562ab5b45d825e	no	6
<b>Warnings:</b>					
<b>Information:</b>					
14	Information Disclosure Statement Letter	Denzel_1974_1_unsubstituted_pyrazolopyridine_esters_DE_original.pdf	2126931 a37d1a988975a095ac184d15d215c285ca583306	no	10
<b>Warnings:</b>					
The page size in the PDF is too large. The pages should be 8.5 x 11 or A4. If this PDF is submitted, the pages will be resized upon entry into the Image File Wrapper and may affect subsequent processing					
<b>Information:</b>					
15	NPL Documents	Denzel_Archiv_der_Pharmazie_1974_EN_trans.pdf	555702 0332e86c3655115c2f56c35b5e78d9e8360442b	no	10
<b>Warnings:</b>					
<b>Information:</b>					
16	Foreign Reference	EP76035_A1_ICI_Americas_pyrazolopyridines.pdf	612378 ba6557762ab1d1c3e3e56816571c828195e587916	no	21
<b>Warnings:</b>					
<b>Information:</b>					
17	Foreign Reference	EP180318_A1_ICI_pyr_pyridine_5_amides.pdf	1884716 42721b6610f9d1153b3e6698935c49b062b1409	no	47
<b>Warnings:</b>					
<b>Information:</b>					
18	Foreign Reference	GB1417489_Squibb_4_amin_o_6_COOH_PZPs.pdf	523468 6b668a39f1d3aee9728e4dab0c04cbb73506e2e	no	10

<b>Warnings:</b>					
<b>Information:</b>					
19	NPL Documents	Giembycz_2000_PDE4_inhibitors_and_Treatment_of_Asthma1.pdf	9282627 832edd806de1b1aa54f8e878c31466851383ce95	no	20
<b>Warnings:</b>					
<b>Information:</b>					
20	NPL Documents	Glass_1979_Biochem_Pharmacol_vol_28_inhibitors_of_PDEs_by_PDE_inhibitors.pdf	1057651 0ed40ce11c265688637f7a13f9e8c3b19c16c91	no	6
<b>Warnings:</b>					
<b>Information:</b>					
21	NPL Documents	Hoehn_Denzel_JHetChem_1972_1.pdf	12886971 c318f65db741067856511fa0723b187b39e10	no	19
<b>Warnings:</b>					
<b>Information:</b>					
22	NPL Documents	Hoehn_JMedChem_1973_16_1340_pirazolo_3_4_b_pyrindines1.pdf	6427047 30e2908e0ee27b11c0f862a18f7b878c21db9f86c	no	7
<b>Warnings:</b>					
<b>Information:</b>					
23	NPL Documents	Horowitz_1972_Psychosomatics_cyclic_AMP_and_anxiety.pdf	1112725 833014a007db6c03eacdb705439ea939b175e05	no	8
<b>Warnings:</b>					
<b>Information:</b>					
24	Foreign Reference	JP2002020386_Ono_PDE4_English_transl.pdf	591221 816e65defe9ba05cd59701d83c561b158c1169	no	71
<b>Warnings:</b>					
<b>Information:</b>					
25	Foreign Reference	jp2002020386A.pdf	1818660 4ec390f7c0c361b5d799de7ef8fcca050bbe747	no	37
<b>Warnings:</b>					
<b>Information:</b>					
26	Foreign Reference	JP2002020386A_Ono_pirazolopyridines.pdf	2288138 0a22a89f7db1e464a38ff72b06e2ba329c290c21	no	37
<b>Warnings:</b>					
<b>Information:</b>					
27	NPL Documents	Kripalani_1981_Xenobiotics_cartazolate_SQ65_396_biotransformation.pdf	1342706 8b228840a2a6493158217b260451bc3db3a5a3	no	8

<b>Warnings:</b>					
<b>Information:</b>					
28	NPL Documents	Ochiai_BioorgMedChemLett_webrelease.pdf	174807 6b54e6b3d469504b7b3d353650e5818ba1f33c9be	no	4
<b>Warnings:</b>					
<b>Information:</b>					
29	NPL Documents	Ochiai_Ono_BioorgMedChem_2004_PZP_PDE4_inhibitors.pdf	378702 d5d619e591c06620629c55eaf038c12c95136113d1	no	12
<b>Warnings:</b>					
<b>Information:</b>					
30	NPL Documents	Ochiai_Ono_June2004_ChemPharmBull_PZP_paper1.pdf	11211593 d8b6d5572c2c1189b85e422a2a39a124c85e193	no	7
<b>Warnings:</b>					
<b>Information:</b>					
31	NPL Documents	Ochiai_Ono_PDE4_pyrazolopyr_5Jan2004_BioorgMedChemLett_14_29_32.pdf	170759 0723011a022579571862198c0c0fab695567639	no	4
<b>Warnings:</b>					
<b>Information:</b>					
32	NPL Documents	Patel_1982_anxiolytic_properties_of_tracazolate.pdf	726686 ce299ae0946d8c34163d134af814528a8d71ae7	no	11
<b>Warnings:</b>					
<b>Information:</b>					
33	NPL Documents	Patel_1985_pharmacology_of_pyrazolopyridines_tracazolate.pdf	510924 8f340ab026da61c550a56644f674c9d5ad190c4d	no	6
<b>Warnings:</b>					
<b>Information:</b>					
34	NPL Documents	Polson_1979_BiochemPharmacol_vol28_PDE_inhibitors_racheal_smooth_muscle_relaxation.pdf	1170920 c9321d090797e093a8719d3793553402ae435938a	no	5
<b>Warnings:</b>					
<b>Information:</b>					
35	Foreign Reference	pp1-75_JP2002020386A_mt2.pdf	13576648 63b3a89e94eab600774053c1d16b4b45454e9	no	75
<b>Warnings:</b>					
<b>Information:</b>					
36	Foreign Reference	pp76_167_JP2002020386A_mt2-2.pdf	13894450 e4b22a366abbd11193265da451c0b234c53ca614	no	92

<b>Warnings:</b>					
<b>Information:</b>					
37	NPL Documents	RBI_1996_catalogue_tracazole_entry.pdf	1033748 1d50e9957ab6ab05e4e4d45b756e0fda36 4a073a98	no	5
<b>Warnings:</b>					
<b>Information:</b>					
38	NPL Documents	Sabitha_1999_SynthComm_route_to_pyrazolo3_4_b_pyridines.pdf	941452 0A2B540b17b2547495f5cc3b1541c552f 2e16f6	no	11
<b>Warnings:</b>					
<b>Information:</b>					
39	NPL Documents	Schenone_2001_BioorgMCL.pdf	105714 2aeefccca34ef5ee2a9283f9b03b06675 7e91508f	no	3
<b>Warnings:</b>					
<b>Information:</b>					
40	NPL Documents	Shi_Daly_DrugDevRes_1997_Pyrazolopyridines_Adenosine_GABAA_receptor_activation.pdf	412548 e4b053e5511cb968bc55d14c30ca73ca 48b37e32	no	16
<b>Warnings:</b>					
<b>Information:</b>					
41	NPL Documents	Weinryb_1975_Excerpta_Med_Int_Congr_Ser_SO20009_as_PDE_inhibitor.pdf	2606626 1adb777c7599c48220357e18bdac02509 48a7641b	no	9
<b>Warnings:</b>					
<b>Information:</b>					
42	Foreign Reference	WO2005_058892A1.pdf	14261179 5d083de4bce9d33727af0ba6798eab0197 073f0e2	no	295
<b>Warnings:</b>					
<b>Information:</b>					
43	Foreign Reference	WO2005_090348A1.pdf	4455196 6e0cde1f8a7164bc7afeac056941f8e537 f5ca26c	no	88
<b>Warnings:</b>					
<b>Information:</b>					
44	Foreign Reference	WO2005_090353_A1.pdf	5951874 4ac9bca7a450a33b0187857669b01121 81607b0d	no	114
<b>Warnings:</b>					
<b>Information:</b>					
45	Foreign Reference	WO2005_090354_A1.pdf	7465726 f8ba213b25c5b68470c15f182e67a4cc91 91a67e8	no	142

<b>Warnings:</b>					
<b>Information:</b>					
46	Foreign Reference	WO0015222A1_Bristol_My s_Squibb.pdf	4683653 6b00afdb6742987ec1095b6a2c2d7f11b 816d1fb	no	113
<b>Warnings:</b>					
<b>Information:</b>					
47	Foreign Reference	WO0123389A2_A3_Neurog en_neuropeptide_Y1_antago nists.pdf	7448846 e02302e1c29eca89f5147b1b1484073 3f13507e	no	218
<b>Warnings:</b>					
<b>Information:</b>					
48	Foreign Reference	WO0144244A1_Merck_pyra zolepyridine_GABA_ligands. pdf	1770950 2b6b64be762f485a0c2540781270568d56 6c036ca50	no	46
<b>Warnings:</b>					
<b>Information:</b>					
49	Foreign Reference	WO0260900A2_A3_Telik_M CP_1_antagonists.pdf	5185732 d54be6b2d99f95ead33hd3a3b002d3b5 4370181	no	124
<b>Warnings:</b>					
<b>Information:</b>					
50	Foreign Reference	WO0281463A1_Telik_MCP_ 1_antagonists.pdf	3525273 9979fcd3b159692b5a21aee8061c2b 3ad090dc	no	84
<b>Warnings:</b>					
<b>Information:</b>					
51	Foreign Reference	WO2002098878A1_Memory _CF3_purines_as_PDE4_inh ibitors.pdf	4680759 b2c3cd6f7920ce6a5803b747ef64e54d0 e9a2c18	no	115
<b>Warnings:</b>					
<b>Information:</b>					
52	Foreign Reference	WO2003016563A2_A3_Exo nhit_treating_neurodegen_e g_ALS_with_PDE4_inhibs_e g_PZPs.pdf	3570128 2038626411ef91440c07000b29f67d786 e24bcecd	no	72
<b>Warnings:</b>					
<b>Information:</b>					
53	Foreign Reference	WO2004024728A2.pdf	14604892 b154d2e3bd9d9dcad65e2b7a3dc1a1712 20140a94	no	293
<b>Warnings:</b>					
<b>Information:</b>					
54	Foreign Reference	WO2004024728A2_A3_P33 108_pyrazolopyr_5_amides esters.pdf	14960457 2d844cc68b40a5040509854493c3f0e5 1fa950	no	299

**Warnings:****Information:**

55	Foreign Reference	WO2004056823A1.pdf	12644820	no	244
			8d776d108bd4d5368cd9756d7798b302915 ba98a33		

**Warnings:****Information:**

56	NPL Documents	Yu_2001JMC_Pyrazolopyridi nes_as_PDE5_Inhibitors1.pdf	542337	no	3
			8c007f21ac96385ee15098854237e548 a5d97305		

**Warnings:****Information:**

<b>Total Files Size (in bytes):</b>	239429155
-------------------------------------	-----------

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

**New Applications Under 35 U.S.C. 111**

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

**National Stage of an International Application under 35 U.S.C. 371**

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

**New International Application Filed with the USPTO as a Receiving Office**

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.